Oncology

Gene editing tool reveals why some patients with cancer fail to respond to immunotherapy.

Several breakthrough cancer drugs were approved in the first half of 2017.

In some cases, chemotherapy can spur cancer cells to spread to other parts of the body.

Paclitaxel chemotherapy may turn on a stress gene that allows cancer cells to escape from the primary tumor.

The receptor helps drive estrogen-receptor positive mammary tumor progression in low estrogen environments.

Understanding why some patients fail to respond to immunotherapy could improve treatments for cancer.

Study identifies previously unknown properties of gold to release anti-cancer drugs inside of tumors.

Young black women are more likely to have aggress breast cancer subtypes than white women.

Triple drug regimen effectively cured patients with hepatitis C virus after they failed to respond to a combination of two oral direct-acting antivirals.

Bruce A. Feinberg, DO, Vice President and Chief Medical Officer of Cardinal Health Specialty Solutions, discusses the expanding role of educational patient support programs in oncology.

Elderly patients with hepatitis C are typically difficult to treat due to poor tolerability and suboptimal response to interferon-based regimens.

Anti-rheumatic drug suppresses activation of a molecular pathway responsible for the disease.

Targeted radiotherapy for breast cancer may improve overall quality of life and reduces side effects.

Top news of the day from across the health care landscape.

The risk of gallbladder cancer was highest in women with a history of periodontal disease.

Studying HER2-positive breast cancer at the cellular level may yield new treatments.

An estimated 2.7 million Americans have hepatitis C, too many for specialists to be the sole provider of anti-HCV therapy.

Top news of the day from across the healthcare landscape.

Top news of the day from across the health care landscape.

Study findings highlight the importance of community-based health interventions that target cancer prevention.

Brandon Shank, PharmD, MPH, BCOP, discusses the role of the oncology pharmacist in providing consultation and maintaining communication with cancer patients during treatment.

Two mutations may cause angioimmunoblastic T cell lymphoma.

Top news of the week from Specialty Pharmacy Times.

Durvalumab is indicated to treat patients with locally-advanced, unresectable non-small cell lung cancer.

Targeting cell mutations could disrupt tumor cell growth without harming non-cancerous cells.

Alectinib (Alcensa) reduced the risk of progression to the central nervous system by 84%.

An approval decision for Alecensa is expected by November 30, 2017.

Three weeks of radiation post-mastectomy observed to be safe and effective for breast cancer patients.

The approach only targets metastatic tissue, reducing negative adverse events associated with chemotherapy.

Top news of the day from across the health care landscape.